New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
04:55 EDTBOTA, BOTA, BOTA, BOTA, IMGN, IMGN, IMGN, IMGN, ARRY, ARRY, ARRY, ARRY, OFIX, OFIX, OFIX, OFIX, CMN, CMN, CMN, CMN, MDCO, MDCO, MDCO, MDCO, TTHI, TTHI, TTHI, TTHI, INO, INO, INO, INO, CNAT, CNAT, CNAT, CNAT, Q, Q, Q, QJefferies to hold a conference
2014 Global Healthcare Conference to be held in New York on June 2-5.
News For BOTA;CNAT;INO;TTHI;MDCO;CMN;OFIX;ARRY;IMGN;Q From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
07:09 EDTIMGNSentiment towards ImmunoGen could rebound, says RBC Capital
Subscribe for More Information
06:34 EDTIMGNImmunoGen appoints Richard Gregory as Chief Scientific Officer
ImmunoGen (IMGN) announced the appointment of Richard Gregory as Executive Vice President, Research and Chief Scientific Officer. Gregory will join the company on January 5, 2015, at which time current CSO, John Lambert, will assume the position of Executive Vice President, Distinguished Research Fellow. Gregory most recently served as senior vice president and head of research for the Sanofi (SNY) Genzyme Research & Development Center.
December 19, 2014
16:31 EDTIMGNOn The Fly: Closing Wrap
Subscribe for More Information
13:30 EDTIMGNImmunoGen downgraded to Market Perform from Outperform at Leerink
Leerink downgraded ImmunoGen to Hold following disappointing MARIANNE trial results.
13:16 EDTIMGNImmunoGen downgraded to Hold from Buy at Jefferies
Subscribe for More Information
12:27 EDTIMGNOn The Fly: Midday Wrap
Subscribe for More Information
09:28 EDTIMGNOn The Fly: Pre-market Movers
Subscribe for More Information
05:36 EDTIMGNImmunoGen reports Phase III MARIANNE study met non-inferiority endpoint
Subscribe for More Information
December 18, 2014
07:01 EDTMDCOThe Medicines Co., SciClone establish strategic partnership
The Medicines Company (MDCO) and SciClone Pharmaceuticals (SCLN) announced the establishment of a strategic partnership for two cardiovascular products in China. The partnership includes an agreement granting SciClone a license and the exclusive rights in China to promote two products of The Medicines Company: ANGIOMAX for Injection, an anticoagulant indicated in patients undergoing percutaneous coronary intervention with provisional use of glycoprotein IIb/IIIa inhibitor and in patients with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome undergoing PCI. A Phase 3 registration trial was completed in China and is currently under review by the China Food and Drug Administration for marketing approval. CLEVIPREX Injectable Emulsion, a third-generation dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or desirable. The clinical trial application for China was filed in 2013. Under the terms of the agreement, SciClone will be responsible for all aspects of commercialization, including pre- and post-launch activities, for both products in the China market excluding Hong Kong and Macau. SciClone has also agreed to assist in the China registration process for both products. Financial terms of the agreement, in addition to net sales royalties payable to The Medicines Company, include the following additional payments to The Medicines Company: an upfront payment; a product support services fee; and regulatory/commercial success milestone payments of up to an aggregate of $50.5M.
06:09 EDTINOInovio inititates DNA immunotherapy trial for several types of cancer
Subscribe for More Information
December 17, 2014
08:06 EDTINOInovio appoints Zane Yang as VP, Clinical Development, Oncology
Subscribe for More Information
December 16, 2014
10:16 EDTARRYHigh option volume stocks:
Subscribe for More Information
December 12, 2014
07:11 EDTARRYOncothyreon announces positive preliminary data from 2 ONT-380 Phase 1b trials
Subscribe for More Information
07:01 EDTARRYOncothyreon announces exclusive agreement with Array BioPharma
Subscribe for More Information
December 11, 2014
08:02 EDTMDCOAlnylam, The Medicines Co. announce initiation of Phase 1 ALN-PCSsc trial
Subscribe for More Information
December 10, 2014
15:14 EDTIMGNImmunoGen volatility at high end of historic range
Subscribe for More Information
08:32 EDTCMNCantel Medical reports Q1 non-GAAP EPS 34c, consensus 28c
Subscribe for More Information
December 8, 2014
12:25 EDTMDCOAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
10:11 EDTMDCOHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use